# Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

> **NCT00276783** · PHASE2 · UNKNOWN · sponsor: **Northwestern University** · enrollment: 31 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma
- Metastatic Cancer

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00276783
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-11
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276783, "Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00276783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*